» Articles » PMID: 27997852

The Roles of Oncogenic MiRNAs and Their Therapeutic Importance in Breast Cancer

Overview
Journal Eur J Cancer
Specialty Oncology
Date 2016 Dec 21
PMID 27997852
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

Since the discovery of tumour suppressive miRNA in 2002, the dysregulation of miRNAs was implicated in many cancers, exhibiting both tumour suppressive and oncogenic roles. Dysregulation of miRNAs was found to be involved in the initiation of oncogenesis, as well as the progression, invasion and metastasis of cancers. While normal miRNA inhibitory functions help regulate gene expression in the cell, oncogenic miRNA, when dysregulated can lead to suppression of critical pathways that control apoptosis, cell cycle progression, growth and proliferation. This suppression allows for the upregulation of pro-oncogenic factors that drive cell survival, growth and proliferation. Due to emerging discoveries, oncogenic miRNAs are proving to be a critical component in cancers, such as breast cancer, and may provide novel avenues for cancer treatment. In this article, we discuss the roles of the most studied oncogenic miRNAs in breast cancer including clusters and families involved as well as the less studied and recently discovered oncogenic miRNAs. These miRNAs provide valuable information into the complexity of regulatory elements affected by their overexpression and the overall impact in the progression of breast cancer. Also, identifying miRNAs causing or leading to resistance or sensitivity to current anti-cancer drugs prior to treatment may lead to an improvement in treatment selection and overall patient response. This review summarizes known and recently discovered miRNAs in literature found to have oncogenic roles in breast cancer initiation and the progression, invasion and metastasis of the disease.

Citing Articles

Combined replacement of lnc-MEG3 and miR-155 elicit tumor suppression in multiple myeloma.

El-Khazragy N, Abdelrahman S, Darwish A, Hemida E Epigenomics. 2025; 17(3):167-177.

PMID: 39815805 PMC: 11816889. DOI: 10.1080/17501911.2025.2453413.


Non-Coding RNAs in Breast Cancer: Diagnostic and Therapeutic Implications.

Benacka R, Szaboova D, Gulasova Z, Hertelyova Z Int J Mol Sci. 2025; 26(1.

PMID: 39795985 PMC: 11719911. DOI: 10.3390/ijms26010127.


The 2024 Nobel Prize in Physiology or Medicine: microRNA Takes Center Stage.

Calin G, Hube F, Ladomery M, Delihas N, Ferracin M, Poliseno L Noncoding RNA. 2024; 10(6.

PMID: 39728607 PMC: 11679529. DOI: 10.3390/ncrna10060062.


Muscle-derived microRNAs correlated with thigh lean mass gains during progressive resistance training in older adults.

OBryan S, Lavin K, Graham Z, Drummer D, Tuggle S, Van Keuren-Jensen K J Appl Physiol (1985). 2024; 137(2):262-273.

PMID: 38932684 PMC: 11424181. DOI: 10.1152/japplphysiol.00680.2023.


Inhibition of Mir-21-5p Affects the Expression of LNCRNA X-Inactive Specific Transcript and Induces Apoptosis in MCF-7 Breast Cancer Cells.

Nejaddehghan S, Zargar S, Oloomi M, Baesi K, Kouhsar M Iran J Public Health. 2024; 53(3):714-725.

PMID: 38919297 PMC: 11194654. DOI: 10.18502/ijph.v53i3.15154.